Seyedahmad Seyedalinaghi, Ramin Shahidi, Arian Afzalian, Parinaz Paranjkhoo, K. Ghorbanzadeh, Hengameh Mojdeganlou, A. Razi, Paniz Mojdeganlou, Mohsen Dashti, Sahar Nooralioghli Parikhani, Afsaneh Ghasemzadeh, Z. Pashaei, A. Karimi, E. Mehraeen, Daniel Hackett, Ahmadi Sepide
{"title":"益生菌预防和治疗covid-19:对现有证据的系统回顾","authors":"Seyedahmad Seyedalinaghi, Ramin Shahidi, Arian Afzalian, Parinaz Paranjkhoo, K. Ghorbanzadeh, Hengameh Mojdeganlou, A. Razi, Paniz Mojdeganlou, Mohsen Dashti, Sahar Nooralioghli Parikhani, Afsaneh Ghasemzadeh, Z. Pashaei, A. Karimi, E. Mehraeen, Daniel Hackett, Ahmadi Sepide","doi":"10.15789/2220-7619-pip-2118","DOIUrl":null,"url":null,"abstract":"Introduction: Clinical evidence suggests that certain probiotics may help treat and prevent viral infections. To date, the effectiveness of probiotics in the alleviation of COVID-19 has not been established. The aim of this systematic review was to assess the role of probiotics in the prevention and treatment of COVID-19. \nMethods: An extensive search of four electronic databases was performed which included Embase, Scopus, Web of Science, and PubMed from November 2019 to June 2022. After reviewing the references list of related articles additional studies were identified. A multiple combination of keywords validated by MESH were used to search the databases. Study selection was performed according to an inclusion and exclusion criteria. \nResults: Twenty-three articles met the study inclusion criteria. Six articles were conducted in vitro while the remaining studies were conducted in the human population (in vivo). The type of probiotic was defined in eighteen studies. There were two studies that used supplements (vitamins, herbals, minerals, etc.) in addition to probiotics. The largest sample size was 44,585 participants which were from a study that used an application-based survey. The majority of studies found that probiotics had a positive effect on the COVID-19 disease. The benefits included early remission of COVID-19 symptoms and a shorter duration of sickness (10 studies), lower mortality rates (3 studies), and decreased hospitalization and length of stay (3 studies). Six in vitro studies found that probiotics were beneficial against SARS-CoV-2 through antiviral effects. There were only two studies that found probiotics to be ineffective or caused negative effects when consumed in COVID-19 patients. \nConclusion: Available evidence supports the antiviral role of probiotics on prevention and treatment of COVID-19. The antiviral potential of Lactobacillus paracasei metabolite PlnE and PlnFagainst SARS-CoV-2 may explain the effectiveness of probiotics on COVID-19.","PeriodicalId":21412,"journal":{"name":"Russian Journal of Infection and Immunity","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PROBIOTICS IN PREVENTION AND TREATMENT OF COVID-19: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE\",\"authors\":\"Seyedahmad Seyedalinaghi, Ramin Shahidi, Arian Afzalian, Parinaz Paranjkhoo, K. Ghorbanzadeh, Hengameh Mojdeganlou, A. Razi, Paniz Mojdeganlou, Mohsen Dashti, Sahar Nooralioghli Parikhani, Afsaneh Ghasemzadeh, Z. Pashaei, A. Karimi, E. Mehraeen, Daniel Hackett, Ahmadi Sepide\",\"doi\":\"10.15789/2220-7619-pip-2118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Clinical evidence suggests that certain probiotics may help treat and prevent viral infections. To date, the effectiveness of probiotics in the alleviation of COVID-19 has not been established. The aim of this systematic review was to assess the role of probiotics in the prevention and treatment of COVID-19. \\nMethods: An extensive search of four electronic databases was performed which included Embase, Scopus, Web of Science, and PubMed from November 2019 to June 2022. After reviewing the references list of related articles additional studies were identified. A multiple combination of keywords validated by MESH were used to search the databases. Study selection was performed according to an inclusion and exclusion criteria. \\nResults: Twenty-three articles met the study inclusion criteria. Six articles were conducted in vitro while the remaining studies were conducted in the human population (in vivo). The type of probiotic was defined in eighteen studies. There were two studies that used supplements (vitamins, herbals, minerals, etc.) in addition to probiotics. The largest sample size was 44,585 participants which were from a study that used an application-based survey. The majority of studies found that probiotics had a positive effect on the COVID-19 disease. The benefits included early remission of COVID-19 symptoms and a shorter duration of sickness (10 studies), lower mortality rates (3 studies), and decreased hospitalization and length of stay (3 studies). Six in vitro studies found that probiotics were beneficial against SARS-CoV-2 through antiviral effects. There were only two studies that found probiotics to be ineffective or caused negative effects when consumed in COVID-19 patients. \\nConclusion: Available evidence supports the antiviral role of probiotics on prevention and treatment of COVID-19. The antiviral potential of Lactobacillus paracasei metabolite PlnE and PlnFagainst SARS-CoV-2 may explain the effectiveness of probiotics on COVID-19.\",\"PeriodicalId\":21412,\"journal\":{\"name\":\"Russian Journal of Infection and Immunity\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Journal of Infection and Immunity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15789/2220-7619-pip-2118\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Infection and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15789/2220-7619-pip-2118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
临床证据表明,某些益生菌可能有助于治疗和预防病毒感染。迄今为止,益生菌在缓解COVID-19方面的有效性尚未得到证实。本系统综述的目的是评估益生菌在预防和治疗COVID-19中的作用。方法:从2019年11月至2022年6月对Embase、Scopus、Web of Science和PubMed四个电子数据库进行广泛检索。在查阅相关文献的参考文献列表后,确定了其他研究。使用MESH验证的多个关键词组合进行数据库搜索。根据纳入和排除标准进行研究选择。结果:23篇文章符合纳入标准。六篇文章是在体外进行的,其余的研究是在人体内进行的。在18项研究中定义了益生菌的类型。除了益生菌,还有两项研究使用了补充剂(维生素、草药、矿物质等)。最大的样本量是44,585名参与者,这些参与者来自一项基于应用程序的调查研究。大多数研究发现,益生菌对COVID-19疾病有积极作用。益处包括早期缓解COVID-19症状和缩短病程(10项研究),降低死亡率(3项研究),减少住院时间和住院时间(3项研究)。六项体外研究发现,益生菌通过抗病毒作用对SARS-CoV-2有益。只有两项研究发现,在COVID-19患者中食用益生菌是无效的或会产生负面影响。结论:现有证据支持益生菌在预防和治疗COVID-19中的抗病毒作用。副干酪乳杆菌代谢物PlnE和plnf2对SARS-CoV-2的抗病毒潜力可能解释了益生菌对COVID-19的有效性。
PROBIOTICS IN PREVENTION AND TREATMENT OF COVID-19: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE
Introduction: Clinical evidence suggests that certain probiotics may help treat and prevent viral infections. To date, the effectiveness of probiotics in the alleviation of COVID-19 has not been established. The aim of this systematic review was to assess the role of probiotics in the prevention and treatment of COVID-19.
Methods: An extensive search of four electronic databases was performed which included Embase, Scopus, Web of Science, and PubMed from November 2019 to June 2022. After reviewing the references list of related articles additional studies were identified. A multiple combination of keywords validated by MESH were used to search the databases. Study selection was performed according to an inclusion and exclusion criteria.
Results: Twenty-three articles met the study inclusion criteria. Six articles were conducted in vitro while the remaining studies were conducted in the human population (in vivo). The type of probiotic was defined in eighteen studies. There were two studies that used supplements (vitamins, herbals, minerals, etc.) in addition to probiotics. The largest sample size was 44,585 participants which were from a study that used an application-based survey. The majority of studies found that probiotics had a positive effect on the COVID-19 disease. The benefits included early remission of COVID-19 symptoms and a shorter duration of sickness (10 studies), lower mortality rates (3 studies), and decreased hospitalization and length of stay (3 studies). Six in vitro studies found that probiotics were beneficial against SARS-CoV-2 through antiviral effects. There were only two studies that found probiotics to be ineffective or caused negative effects when consumed in COVID-19 patients.
Conclusion: Available evidence supports the antiviral role of probiotics on prevention and treatment of COVID-19. The antiviral potential of Lactobacillus paracasei metabolite PlnE and PlnFagainst SARS-CoV-2 may explain the effectiveness of probiotics on COVID-19.